A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Clinical trial NCT01596621 · COMPLETED
Trial details
- NCT number
- NCT01596621
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-06
- Primary completion
- 2015-06-18
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.